{"title":"A multimodal machine learning model for the stratification of breast cancer risk","authors":"Xuejun Qian, Jing Pei, Chunguang Han, Zhiying Liang, Gaosong Zhang, Na Chen, Weiwei Zheng, Fanlun Meng, Dongsheng Yu, Yixuan Chen, Yiqun Sun, Hanqi Zhang, Wei Qian, Xia Wang, Zhuoran Er, Chenglu Hu, Hui Zheng, Dinggang Shen","doi":"10.1038/s41551-024-01302-7","DOIUrl":null,"url":null,"abstract":"<p>Machine learning models for the diagnosis of breast cancer can facilitate the prediction of cancer risk and subsequent patient management among other clinical tasks. For the models to impact clinical practice, they ought to follow standard workflows, help interpret mammography and ultrasound data, evaluate clinical contextual information, handle incomplete data and be validated in prospective settings. Here we report the development and testing of a multimodal model leveraging mammography and ultrasound modules for the stratification of breast cancer risk based on clinical metadata, mammography and trimodal ultrasound (19,360 images of 5,216 breasts) from 5,025 patients with surgically confirmed pathology across medical centres and scanner manufacturers. Compared with the performance of experienced radiologists, the model performed similarly at classifying tumours as benign or malignant and was superior at pathology-level differential diagnosis. With a prospectively collected dataset of 191 breasts from 187 patients, the overall accuracies of the multimodal model and of preliminary pathologist-level assessments of biopsied breast specimens were similar (90.1% vs 92.7%, respectively). Multimodal models may assist diagnosis in oncology.</p>","PeriodicalId":19063,"journal":{"name":"Nature Biomedical Engineering","volume":"21 1","pages":""},"PeriodicalIF":26.8000,"publicationDate":"2024-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature Biomedical Engineering","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.1038/s41551-024-01302-7","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENGINEERING, BIOMEDICAL","Score":null,"Total":0}
引用次数: 0
Abstract
Machine learning models for the diagnosis of breast cancer can facilitate the prediction of cancer risk and subsequent patient management among other clinical tasks. For the models to impact clinical practice, they ought to follow standard workflows, help interpret mammography and ultrasound data, evaluate clinical contextual information, handle incomplete data and be validated in prospective settings. Here we report the development and testing of a multimodal model leveraging mammography and ultrasound modules for the stratification of breast cancer risk based on clinical metadata, mammography and trimodal ultrasound (19,360 images of 5,216 breasts) from 5,025 patients with surgically confirmed pathology across medical centres and scanner manufacturers. Compared with the performance of experienced radiologists, the model performed similarly at classifying tumours as benign or malignant and was superior at pathology-level differential diagnosis. With a prospectively collected dataset of 191 breasts from 187 patients, the overall accuracies of the multimodal model and of preliminary pathologist-level assessments of biopsied breast specimens were similar (90.1% vs 92.7%, respectively). Multimodal models may assist diagnosis in oncology.
期刊介绍:
Nature Biomedical Engineering is an online-only monthly journal that was launched in January 2017. It aims to publish original research, reviews, and commentary focusing on applied biomedicine and health technology. The journal targets a diverse audience, including life scientists who are involved in developing experimental or computational systems and methods to enhance our understanding of human physiology. It also covers biomedical researchers and engineers who are engaged in designing or optimizing therapies, assays, devices, or procedures for diagnosing or treating diseases. Additionally, clinicians, who make use of research outputs to evaluate patient health or administer therapy in various clinical settings and healthcare contexts, are also part of the target audience.